These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 31387016)

  • 1. Role of the transcriptional coactivators YAP/TAZ in liver cancer.
    Zhang S; Zhou D
    Curr Opin Cell Biol; 2019 Dec; 61():64-71. PubMed ID: 31387016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Research advances in the role of the Hippo-YAP/TAZ signaling pathway in primary liver cancer].
    Guo LW; Shao GL
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):878-880. PubMed ID: 29325286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
    Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
    Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.
    Moya IM; Castaldo SA; Van den Mooter L; Soheily S; Sansores-Garcia L; Jacobs J; Mannaerts I; Xie J; Verboven E; Hillen H; Algueró-Nadal A; Karaman R; Van Haele M; Kowalczyk W; De Waegeneer M; Verhulst S; Karras P; van Huffel L; Zender L; Marine JC; Roskams T; Johnson R; Aerts S; van Grunsven LA; Halder G
    Science; 2019 Nov; 366(6468):1029-1034. PubMed ID: 31754005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.
    Liu Y; Wang X; Yang Y
    Clin Mol Hepatol; 2020 Oct; 26(4):742-750. PubMed ID: 32981290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.
    Shi H; Zou Y; Zhong W; Li Z; Wang X; Yin Y; Li D; Liu Y; Li M
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15311-15322. PubMed ID: 37608027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
    Budel SJ; Penning MM; Penning LC
    Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
    Nishina H
    Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two Hippo signaling modules orchestrate liver size and tumorigenesis.
    Qi S; Zhong Z; Zhu Y; Wang Y; Ma M; Wang Y; Liu X; Jin R; Jiao Z; Zhu R; Sha Z; Dang K; Liu Y; Lim DS; Mao J; Zhang L; Yu FX
    EMBO J; 2023 Jun; 42(11):e112126. PubMed ID: 36919851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis.
    Patel SH; Camargo FD; Yimlamai D
    Gastroenterology; 2017 Feb; 152(3):533-545. PubMed ID: 28003097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
    Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
    Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the ambivalent role of YAP/TAZ in human cancers.
    Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
    J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of signaling pathways regulating YAP/TAZ activity.
    Heng BC; Zhang X; Aubel D; Bai Y; Li X; Wei Y; Fussenegger M; Deng X
    Cell Mol Life Sci; 2021 Jan; 78(2):497-512. PubMed ID: 32748155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. USP1 modulates hepatocellular carcinoma progression via the Hippo/TAZ axis.
    Liu D; Li Q; Zang Y; Li X; Li Z; Zhang P; Feng C; Yang P; Cui J; Sun Y; Wei T; Su P; Zhao X; Yang H; Ding Y
    Cell Death Dis; 2023 Apr; 14(4):264. PubMed ID: 37041150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration.
    Lu L; Finegold MJ; Johnson RL
    Exp Mol Med; 2018 Jan; 50(1):e423. PubMed ID: 29303509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
    Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
    Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting YAP and Hippo signaling pathway in liver cancer.
    Liu AM; Xu MZ; Chen J; Poon RT; Luk JM
    Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.